Skip to main content
SpringerLink
Log in

Panitumumab in the Treatment of Metastatic Colorectal Cancer

Profile Report

  • Adis Profile Report
  • Published:
BioDrugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Hoy SM, Wagstaff AJ. Panitumumab: in the treatment of metastatic colorectal cancer. Drugs 2006; 66(15): 2005–14

    Article  PubMed  CAS  Google Scholar 

  2. Malik I. Panitumumab: a viewpoint by Imtiaz Malik. Drugs 2006; 66(15): 2015

    Article  Google Scholar 

  3. Ranson M. Panitumumab: a viewpoint by Malcolm Ranson. Drugs 2006; 66(15): 2015–6

    Article  Google Scholar 

  4. World Health Organization. Cancer [online]. Available from URL: http://www.who.int/mediacentre/factsheets/fs297/en/print.html [Accessed 2006 May 18]

  5. Labianca RF, Beretta GD, Pessi MA. Colorectal cancer: disease management considerations. Drugs 2001; 61(12): 1751–64

    Article  PubMed  CAS  Google Scholar 

  6. Jefford M, Zalcberg J. Recent advances in the systemic therapy of metastatic colorectal cancer. Am J Cancer 2005; 4(1): 15–34

    Article  CAS  Google Scholar 

  7. Coutinho AK, Rocha Lima CMS. Metastatic colorectal cancer: systemic treatment in the new millennium. Cancer Control 2003; 10(3): 224–38

    PubMed  Google Scholar 

  8. Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ 2000 Sep 2; 321(7260): 531–5

    Article  PubMed  CAS  Google Scholar 

  9. Alekshun T, Garrett C. Targeted therapies in the treatment of colorectal cancers. Cancer Control 2005 Apr; 12(2): 105–10

    PubMed  Google Scholar 

  10. Venook AP. Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma. Cancer 2005; 103(12): 2435–46

    Article  PubMed  CAS  Google Scholar 

  11. McWilliams RR, Erlichman C. Novel therapeutics in colorectal cancer. Dis Colon Rectum 2005; 48(8): 1632–50

    Article  PubMed  Google Scholar 

  12. Ranson M. Technology evaluation: ABX-EGF, Abgenix/Amgen. Curr Opin Mol Ther 2003 Oct; 5(5): 541–6

    PubMed  CAS  Google Scholar 

  13. Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer 2004 Dec; 11(4): 689–708

    Article  PubMed  CAS  Google Scholar 

  14. Veronese ML, O’Dwyer PJ. Monoclonal antibodies in the treatment of colorectal cancer. Eur J Cancer 2004 Jun; 40(9): 1292–301

    Article  PubMed  CAS  Google Scholar 

  15. Levene AP, Singh G, Palmieri C. Therapeutic monoclonal antibodies in oncology. J R Soc Med 2005; 98(4): 146–52

    Article  PubMed  CAS  Google Scholar 

  16. Yang X-D, Jia X-C, Corvalan JRF, et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001; 38: 17–23

    Article  PubMed  CAS  Google Scholar 

  17. Weiner LM. Fully human therapeutic monoclonal antibodies. J Immunother 2006 Jan-Feb; 29(1): 1–9

    Article  PubMed  CAS  Google Scholar 

  18. Peeters M, Van Custem E, Siena S, et al. A phase III, multicenter, randomized controlled trial of panitumumab plus best supportive care (BSC) versus BSC alone in patients with metastatic colorectal cancer [abstract no. CP-1] plus oral presentation at 97th Annual Meeting of the American Association for Cancer Research; 2006 Apr 1-5; Washington, DC

  19. Berlin J, Neubauer M, Swanson P, et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing ≥10% epidermal growth factor receptor (EGFr) [abstract no. 3548]. J Clin Oncol 2006; 24 (18 Suppl. Pt 1): 158s. Plus poster presented at the 42nd American Society of Clinical Oncology (ASCO) Annual Meeting; 2006 Jun 2–6; Atlanta (GA)

    Google Scholar 

  20. Hecht J, Mitchell E, Baranda J, et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing low (<l–9%) or negative (<1 %) levels of epidermal growth factor receptor (EGFr) [abstract no. 3547]. J Clin Oncol 2006; 24 (18 Suppl. Pt 1): 157s. Plus poster presented at the 42nd American Society of Clinical Oncology (ASCO) Annual Meeting; 2006 Jun 2–6; Atlanta (GA)

    Article  Google Scholar 

  21. Malik I, Hecht JR, Patnaik A, et al. Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer [abstract no. 3520]. J Clin Oncol 2005; 23 (16 Suppl. Pt I): 251S. Plus poster presented at the 41st American Society of Clinical Oncology (ASCO) Annual Meeting; 2005 May 13–17; Orlando (FL)

    Google Scholar 

  22. Hecht J, Posey S, Tchekmedyian S, et al. Panitumumab in combination with 5-fluorouracil, leucovorin, and irinotecan or FOLFIRI for first-line treatment of metastatic colorectal cancer [abstract no. 237]. 3rd Annual Gastrointestinal Cancers Symposium; 2006 Jan 26–28; San Francisco (CA)

  23. Amgen. Vectibix™ [panitumumab] prescribing information [online]. Available from URL: http://www.fda.gov/ [Accessed 2006 Oct 3]

Download references

Author information

Authors and Affiliations

  1. Wolters Kluwer Health ¦ Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland, 1311, New Zealand

    Sheridan M. Hoy & Antona J. Wagstaff

  2. Wolters Kluwer Health, Conshohocken, Pennsylvania, USA

    Sheridan M. Hoy & Antona J. Wagstaff

Authors
  1. Sheridan M. Hoy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Antona J. Wagstaff
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Adapted and reproduced from Drugs 2006; 66 (15): 2005–16. [1-3] The manufacturer of the agent under review was offered an opportunity to comment on the original article[1] during the peer review process; changes based on any comments received were made on the basis of scientific and editorial merit

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hoy, S.M., Wagstaff, A.J. Panitumumab in the Treatment of Metastatic Colorectal Cancer. BioDrugs 21, 135–137 (2007). https://doi.org/10.2165/00063030-200721020-00011

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-200721020-00011

Keywords

Search

Navigation